New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
10:02 EDTACT, JEC, MNK, MW, MYL, PKY, PRGO, SLXP, TEVA, VRX, HST, HSP, GT, ARCP, BDN, BR, CBI, CTB, DRH, ENDP, EQR, ESS, VTROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at Deutsche Bank... American Realty (ARCP) initiated with a Perform at Oppenheimer... Brandywine Realty (BDN) initiated with a Neutral at Mizuho... Broadridge (BR) initiated with an Outperform at Raymond James... Chicago Bridge & Iron (CBI) initiated with a Market Perform at Wells Fargo... Cooper Tire (CTB) initiated with a Neutral at JPMorgan... DiamondRock (DRH) initiated with a Neutral at ISI Group... Endo (ENDP) initiated with a Buy at Deutsche Bank... Equity Residential (EQR) initiated with a Neutral at Mizuho... Essex Property Trust (ESS) initiated with a Buy at Mizuho... Fluor (FLR) initiated with an Outperform at Wells Fargo... Goodyear Tire (GT) initiated with an Overweight at JPMorgan... Hospira (HSP) initiated with a Hold at Deutsche Bank... Host Hotels (HST) initiated with a Neutral at ISI Group... Jacobs Engineering (JEC) initiated with an Outperform at Wells Fargo... Jazz Pharmaceutical initiated with a Buy at Buckingham... Mallinckrodt (MNK) initiated with a Buy at Deutsche Bank... Men's Wearhouse (MW) reinstated with a Buy at Goldman... Mylan (MYL) initiated with a Buy at Deutsche Bank... Parkway Properties (PKY) initiated with a Neutral at Mizuho... Perrigo (PRGO) initiated with a Buy at Deutsche Bank... Salix (SLXP) initiated with a Hold at Deutsche Bank... Teva (TEVA) initiated with a Buy at Deutsche Bank... Valeant (VRX) initiated with a Hold at Deutsche Bank... Ventas (VTR) initiated with a Buy at Mizuho.
News For ACT;ARCP;BDN;BR;CBI;CTB;DRH;ENDP;EQR;ESS;GT;HSP;HST;JEC;MNK;MW;MYL;PKY;PRGO;SLXP;TEVA;VRX;VTR From The Last 14 Days
Check below for free stories on ACT;ARCP;BDN;BR;CBI;CTB;DRH;ENDP;EQR;ESS;GT;HSP;HST;JEC;MNK;MW;MYL;PKY;PRGO;SLXP;TEVA;VRX;VTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 4, 2014
17:17 EDTMYLMylan initiated with a Hold at ISI Group
Subscribe for More Information
17:16 EDTVRXValeant initiated with a Buy at ISI Group
Target $159.
17:16 EDTACTActavis initiated with a Buy at ISI Group
Subscribe for More Information
17:16 EDTTEVATeva initiated with a Buy at ISI Group
Subscribe for More Information
16:42 EDTVTRVentas re-audit completed with no changes to previously reported financials
Subscribe for More Information
13:12 EDTHSPFDA posts approval of Hospira's Milrinone Lactate
Reference Link
10:29 EDTESSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:44 EDTVRXValeant, Ackman deliver another 2.8% consent vote to Allergan, CNBC reports
Valeant (VRX) and Bill Ackman delivered another 2.8% consent vote to Allergan, bringing its total vote to call a special meeting to 33.8%, CNBC's David Faber reports, citing sources. A special meeting has been set for December 18, Faber added.
09:02 EDTMNKMallinckrodt announces MNK-155 Phase 3 efficacy trial met primary endpoint
Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014 on September 2-6. In addition to the Phase 3 study, Mallinckrodt will present data at PAINWeek from several other MNK-155 trials, including the pharmacokinetics, safety and subjective effects of abuse-related characteristics.
08:02 EDTTEVATeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:24 EDTGTGoodyear Tire management to meet with Deutsche Bank
Meeting to be held in New York on September 4 hosted by Deutsche Bank.
07:21 EDTTEVAMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
06:24 EDTESSEssex Property Trust downgraded to Neutral from Buy at UBS
UBS downgraded Essex Property to Neutral based on valuation. Price target remains $195.
05:20 EDTARCPAmerican Realty initiated with a Market Perform at Wells Fargo
Price target range $13-$14.
September 3, 2014
11:54 EDTHSPHospira talks to acquire Danone nutrition unit stall, Reuters reports
Subscribe for More Information
11:36 EDTHSPHospira talks to acquire Danone nutrition unit stall, Reuters reports
09:07 EDTMNKMallinckrodt reported MNK-155 HAL study data
Subscribe for More Information
07:53 EDTMNKMallinckrodt management to meet with Deutsche Bank
Meeting to be held in New York on September 3 hosted by Deutsche Bank.
06:07 EDTMWJos. A. Bank announces early termination agreement with Jim's Formal Wear
Subscribe for More Information
05:44 EDTTEVATeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use